Skip to main content

Table 2 Characteristics of the 28 patients with invasive candidiasis in a single-centre study over 10 years

From: Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis

Total number of invasive candidiasis episodes

28

Distribution of invasive Candida species

-

C. albicans

4

C. glabrata

8

C. krusei

4

C. norvegensis

3

C. inconspicua

2

C. dubliensis

2

C. parapsilosis

2

C. kefyr, C. guilliermondii, C. tropicalis (each 1)

3

Gender

 

Number of males

12 (42.9%)

Number of females

16 (57.1%)

Median age in years

47 (31–63 IQR)

Underlying conditions:

 

Number of patients with:

 

Acute myeloid leukaemia

16

Acute lymphatic leukaemia

3

Myelodysplastic syndrome

3

Non-Hodgkin lymphoma and plasmocytoma (2 each)

4

Aplasia of unknown origin, hereditary mitochondropathy (1 each)

2

Haematological treatments

 

Number of allogeneic HSCT recipients

15

PBSC recipients

13

BMT recipient

1

Cord blood recipient

1

Related/unrelated donor

1/14 (6.7%/93.3%)

Conditioning chemotherapy before HSCT

2

Induction chemotherapy

8

Other chemotherapies (e.g. consolidation, not specified)

3

Other risk factors for invasive candidiasis

 

A stay in the ICU within 7 days prior to onset of invasive candidiasis

4

Number of patients in neutropenia (<500/uL) at time of invasive candidiasis

19

Median duration (days) of neutropenia until diagnosis of invasive candidiasis

13 (7–24 IQR)

Number of patients with CMV disease before invasive candidiasis episode

2

Number of patients with onset of GvHD before invasive candidiasis

5

Outcome

 

Death (all cause) within 30 days after diagnosis of invasive candidiasis

10